

# Early Findings of Keratoconus, Clinical Management, and the Challenge in Stopping its Progression

Mimoza Ismaili\*

Department of Ophthalmology, Faculty of Medicine, University of Pristina "Hasan Prishtina"  
Prishtina, Kosovo

## Abstract

**Background:** Keratoconus (KCN) is considered a bilateral corneal ectatic disorder characterized by cone-like steepening of the cornea and irregular stromal thinning, which can lead to decreased visual acuity. This study aimed to assess the prevalence and risk factors for the KCN development in Kosovo.

**Methods and Results:** This retrospective study was conducted in the Department of Ophthalmology at the University Clinical Center of Kosovo. The study included 131 respondents, with a total of 262 eyes. Keratometry basis parameters, such as flat keratometry (K1), and steep keratometry (K2), and maximal corneal curvature (Kmax) were determined. Corneal pachymetry was applied to measure the thickness of the cornea. Staging of KCN was done according to the adapted Amsler-Krumeich staging classification system (AK) for anterior data and corneal thickness (CT). Of 262 examined eyes, 240 (91.6%) were KCN eyes, 2 (0.8%) were suspect for KCN, and 20 (7.6%) were normal. KCN Stage 1 on the AK classification was predominant ( $P < 0.001$ ). KCN Stage 1 on the AK classification was predominant (52.9%) ( $P < 0.001$ ). We did not find a statistically significant difference between the mean age of patients and the KCN stage ( $P = 0.235$ ). The level of K1 was significantly lower in the non-KCN group ( $41.4 \pm 0.5$  D) compared to KCN, and with increasing KCN stage, the K1 value significantly increased, reaching a maximum level in Stage 4 ( $53.3 \pm 4.3$  D) ( $P = 0.0000$ ). A similar trend was typical for K2 and Kmax: from  $44.7 \pm 5.1$  D and  $44.5 \pm 3.1$  D, respectively, in the non-KCN group to  $55.6 \pm 4.9$  D and  $65.3 \pm 8.3$  D, respectively, in KCN Stage 4 ( $P = 0.0000$ ). Regarding the CT, the highest values were in the non-KCN group ( $504.0 \pm 27.6$   $\mu\text{m}$ ), gradually decreasing from KCN Stage 1 to Stage 4 ( $466.2 \pm 36.0$   $\mu\text{m}$  vs.  $378.6 \pm 95.0$   $\mu\text{m}$ ,  $P = 0.0000$ ).

**Conclusion:** Screening programs that detect KCN at its earliest grade are the key to enabling early management, halting progression, and preserving the quality of visual acuity. (International Journal of Biomedicine. 2024;14(3):428-434.)

**Keywords:** keratoconus • keratometry • corneal thickness • corneal topography

**For citation:** Ismaili M. Early Findings of Keratoconus, Clinical Management, and the Challenge in Stopping its Progression. International Journal of Biomedicine. 2024;14(3):428-434. doi:10.21103/Article14(3)\_OA6

## Abbreviations

AT, apical thickness; CT, corneal thickness; CXL, corneal collagen cross-linking; Km, mean central keratometry; Kmax, maximal corneal curvature.

## Introduction

Keratoconus is a Greek word (kerato: Cornea; konos: Cone), meaning cone-shaped protrusion of the cornea.<sup>(1)</sup> Keratoconus (KCN) is considered a bilateral corneal ectatic disorder characterized by cone-like steepening of the cornea and irregular stromal thinning, which can lead to decreased visual acuity.<sup>(2)</sup> Eye rubbing can be evoked by symptoms of allergy and dryness of the eye.<sup>(3,4)</sup> This disorder has been known

in the middle of the 19th century.<sup>(5)</sup> The disease may begin as unilateral, but finally, the other eye becomes involved.<sup>(6)</sup> New imaging technology, including corneal tomography, has provided an early diagnosis of keratoconus, even before the decrease in visual quality.<sup>(7)</sup> Corneal tomography characterizes the elevation of the front and back corneal surfaces and reconstructs the pachymetric mapping, which has significantly enhanced the sensitivity and specificity for detecting corneal ectasia.<sup>(8,9)</sup> The symptoms and signs of keratoconus vary

depending on severity. In the early stages, it can mimic simple refractive errors with good visual acuity. As it progresses, there is a reduction in best corrected visual acuity (BCVA), distorted vision, and 'ghosting.'<sup>(10)</sup>

## Materials and Methods

This retrospective study was conducted in the Department of Ophthalmology at the University Clinical Center of Kosovo. The study included 131 respondents, with a total of 262 eyes. Age, gender, visual acuity (VA), and clinical signs and symptoms were recorded. Keratometry basis parameters, such as flat keratometry (K1), and steep keratometry (K2), and maximal corneal curvature (Kmax) were determined. Corneal pachymetry was applied to measure the thickness of the cornea. The diagnosis of KCN was confirmed if both eyes were suspect to KCN signs or if one eye was suspect and the contralateral was normal. Eye rubbing was the most frequent clinical sign of KCN in this study.

### Data collection

Of all respondents included in this research, 26 eyes had bilateral KCN, and 26 had unilateral KCN but with different degrees of severity. Furthermore, asymmetric refractive error astigmatism was typical for the mild and moderate KCN forms, while the advanced form was characterized by progressive astigmatism.

Classifications were based on disease evolution, ocular signs, and corneal topography data. Staging of KCN was done according to the adapted Amsler-Krumeich staging classification system (AK) for anterior data and CT: Stage 1 (Km < 48 D), Stage 2 (Km < 53 D, CT > 400 µm), Stage 3 (Km > 53 D, CT > 300 µm), and Stage 4 (Km > 55 D, CT < 300 µm).

Inclusion criteria: Respondents with evident signs of keratoconus in corneal maps (taken from Scheimpflug tomography), respondents with myopia or myopic astigmatism, respondents without eye disease, and those without eye surgery.

Exclusion criteria: Patients with glaucoma and previous corneal refractive surgery procedures, evidence of other anterior segment pathology including corneal opacities, corneal oedema, the respondents with staphyloma, severe cases of KCN, refusal to give consent.

### Procedure

Data collected from respondents with KCN were retrospectively collected for 262 eyes examined over a period of three years. After the informed consent was obtained, the respondents underwent a complete ophthalmic examination, anterior segment evaluation by slit-lamp examination (localized stromal thinning, Fleischer's ring, Vogt's striae, conical protrusion), corneal tomographic by the Pentacam HR system (Oculus, Wetzlar, Germany), and retinoscopy (scissor reflex sign). Objective refraction included autorefractometry, and subjective refraction included (Snellen's visual acuity chart). After testing the right eye, the acuity of the left eye was measured. The results were the same when the left eye was analyzed; thus, right-eye data were presented.

### Statistical data analysis

Statistical analysis was performed using the statistical software package SPSS version 22.0 (SPSS Inc, Armonk, NY: IBM Corp). For the descriptive analysis, results are presented as mean (M) ± standard deviation (SD). Multiple comparisons were performed with one-way ANOVA and a post-hoc Tukey HSD test. Categorical variables were analyzed using the chi-square test. Spearman's rank correlation coefficient ( $r_s$ ) was calculated to measure the strength and direction of the relationship between two variables. A probability value of  $P < 0.05$  was considered statistically significant.

## Results

All respondents included in the research were aged 13–37, with a mean age of  $23.49 \pm 4.9$  years. Only 10.7% of patients had a positive family history. Of the 262 examined eyes, 160 (61.1%) underwent surgical intervention: 67 (41.9%) with the Epi-off technique and 93 (58.1%) with Epi-on (Table 1).

Table 1.

### General characteristics of study patients.

Total patients	131	100.0%
Gender		
M	78	59.5%
F	53	40.5%
Age (year)		
Mean ± SD	23.4 ± 4.9	
Range	13 - 37	
Residence		
Urban	68	51.9%
Rural	63	48.1%
Positive family anamnesis	14	10.7%
Total Eyes	262	100.0%
Treated	160	61.1%
Untreated	102	38.9%
Technique		
Epi-off	67	41.9%
Epi-on	93	58.1%

Out of 76 patients with eye rubbing, 71 (93.4%) had keratoconic eyes, while out of 55 patients who did not have eye rubbing, 50 (90.9%) did not have keratoconic eyes. Patients with KCN were 1.174 times more at risk of having eye rubbing  $RR = 1.174$  (95% CI, 0.747 - 1.842) without significant difference ( $P = 0.486$ ). We did not obtain a substantial correlation between eye rubbing and KCN ( $r_s = 0.046$ , 95% CI: -0.078 to 0.170).

Of 262 examined eyes, 240 (91.6%) were KCN eyes, 2 (0.8%) were suspect for KCN, and 20 (7.6%) were normal. We did not obtain a statistically significant difference in the prevalence of KCN according to gender and KCN stages

( $P>0.05$ ) (Table 2). The right eye was without keratoconic manifestation in 6.9% of patients, without significant difference according to gender ( $P=0.739$ ), while the left eye was without keratoconic manifestation in 8.4% of patients, without significant difference according to gender ( $P=0.999$ ) (Table 2).

**Table 2.**

**KCN eyes according to gender.**

	M		F		Total		P-value
	n	%	n	%	n	%	
Total	78	100.0	53	100.0	131	100.0	
OD							
KCN	71	91.0	50	94.3	121	92.4	0.739
non-KCN	6	7.7	3	5.7	9	6.9	
Suspect	1	1.3	-	-	1	0.8	
OS							
KCN	71	91.0	48	90.6	119	90.8	0.999
non-KCN	7	9.0	4	7.5	11	8.4	
Suspect	-	-	1	1.9	1	0.8	

KCN - keratoconic eyes, non-KCN - non-keratoconic eyes, Suspect - keratoconic eyes

KCN Stage 1 on the AK classification was predominant (52.9%) ( $P<0.001$ ). We did not find a statistically significant difference between the mean age of patients and the KCN stage ( $P=0.235$ ) (Table 3).

**Table 4.**

**Keratometry parameters, VA, and CT among study groups.**

Variable	Non-KCN n=20 (1)	Suspect n = 2 (2)	Stage 1 n=144 (3)	Stage 2 n = 64 (4)	Stage 3 n=15 (5)	Stage 4 n=17 (6)	Statistics
K1, D	41.4±0.5	45.0±3.2	47.5±2.0	49.3±2.6	50.5±5.5	53.3±4.3	F=47.4293 P=0.0000 P <sub>1-2</sub> =0.4255, P <sub>1-3</sub> =0.0000, P <sub>1-4</sub> =0.0000, P <sub>1-5</sub> =0.0000, P <sub>1-6</sub> =0.0000, P <sub>2-3</sub> =0.7567, P <sub>2-4</sub> =0.1970, P <sub>2-5</sub> =0.0592, P <sub>2-6</sub> =0.0004, P <sub>3-4</sub> =0.0001, P <sub>3-5</sub> =0.0004, P <sub>3-6</sub> =0.0000, P <sub>4-5</sub> =0.5939, P <sub>4-6</sub> =0.0000, P <sub>5-6</sub> =0.0310
K2, D	44.7±5.1	47.1±2.8	45.4±2.3	48.8±3.5	52.5±5.8	55.6±4.9	F=42.1507 P=0.0000 P <sub>1-2</sub> =0.9288, P <sub>1-3</sub> =0.9524, P <sub>1-4</sub> =0.0000, P <sub>1-5</sub> =0.0000, P <sub>1-6</sub> =0.0000, P <sub>2-3</sub> =0.9805, P <sub>2-4</sub> =0.9812, P <sub>2-5</sub> =0.2718, P <sub>2-6</sub> =0.0104, P <sub>3-4</sub> =0.0000, P <sub>3-5</sub> =0.0000, P <sub>3-6</sub> =0.0000, P <sub>4-5</sub> =0.0021, P <sub>4-6</sub> =0.0000, P <sub>5-6</sub> =0.0993
Kmax, D	44.5±3.1	46.9±1.6	49.1±4.9	53.1±5.2	59.5±5.4	65.3±8.3	F=46.5169 P=0.0000 P <sub>1-2</sub> =0.9890, P <sub>1-3</sub> =0.0031, P <sub>1-4</sub> =0.0000, P <sub>1-5</sub> =0.0000, P <sub>1-6</sub> =0.0000, P <sub>2-3</sub> =0.9911, P <sub>2-4</sub> =0.5521, P <sub>2-5</sub> =0.0168, P <sub>2-6</sub> =0.0000, P <sub>3-4</sub> =0.0000, P <sub>3-5</sub> =0.0000, P <sub>3-6</sub> =0.0000, P <sub>4-5</sub> =0.0003, P <sub>4-6</sub> =0.0000, P <sub>5-6</sub> =0.0209
VA(sc)	0.77±0.27	0.95±0.07	0.47±0.30	0.32±0.25	0.24±0.26	0.19±0.22	F=13.8236 P=0.0000 P <sub>1-2</sub> =0.9533, P <sub>1-3</sub> =0.0001, P <sub>1-4</sub> =0.0000, P <sub>1-5</sub> =0.0000, P <sub>1-6</sub> =0.0000, P <sub>2-3</sub> =0.1542, P <sub>2-4</sub> =0.0225, P <sub>2-5</sub> =0.0106, P <sub>2-6</sub> =0.0043, P <sub>3-4</sub> =0.0054, P <sub>3-5</sub> =0.0310, P <sub>3-6</sub> =0.0016, P <sub>4-5</sub> =0.91773, P <sub>4-6</sub> =0.5277, P <sub>5-6</sub> =0.9959
CT, μm	504.0±27.6	499.0±48.1	466.2±36.0	446.9±31.7	392.4±114.2	378.6±95.0	F=20/9634 P=0.0000 P <sub>1-2</sub> =0.9999, P <sub>1-3</sub> =0.0142, P <sub>1-4</sub> =0.0001, P <sub>1-5</sub> =0.0000, P <sub>1-6</sub> =0.0000, P <sub>2-3</sub> =0.9307, P <sub>2-4</sub> =0.6593, P <sub>2-5</sub> =0.0408, P <sub>2-6</sub> =0.0119, P <sub>3-4</sub> =0.0847, P <sub>3-5</sub> =0.0000, P <sub>3-6</sub> =0.0000, P <sub>4-5</sub> =0.0014, P <sub>4-6</sub> =0.0000, P <sub>5-6</sub> =0.9655

**Table 3.**

**The average age of patients according to the KCN stages.**

Group	Age (year)				
	N	Mean	SD	Min	Max
Non-keratoconic	11	20.0	3.8	15	26
Suspect	1	23.0	-	23	23
KCN					
Stage 1	63	23.3	4.1	15	35
Stage 2	38	24.0	5.6	13	34
Stage 3	8	26.8	6.7	20	37
Stage 4	10	22.4	4.8	16	33
Total	131	23.4	4.9	13	37
Statistics	P=0.235				

Keratometry readings are presented in Table 4. The level of K1 was significantly lower in the non-KCN group (41.4±0.5 D) compared to KCN, and with increasing KCN stage, the K1 value significantly increased, reaching a maximum level in Stage 4 (53.3±4.3 D). A similar trend was typical for K2 and Kmax: from 44.7±5.1 D and 44.5±3.1 D, respectively, in the non-KCN group to 55.6±4.9 D and 65.3±8.3 D, respectively, in KCN Stage 4. Changes in CT were opposite: the highest values were in the non-KCN group (504.0±27.6 μm), gradually decreasing from KCN Stage 1 to Stage 4 (466.2±36.0 μm vs. 378.6±95.0 μm,  $P=0.0000$ ). However, no significant differences between the non-KCN group and the suspected group were noted for all indicators, possibly due to the small size of the suspected group (Table 4).

## Discussion

KCN usually appears at puberty and progresses until the 30s and 40s. Its progression rate varies between individuals but is generally higher in younger patients.<sup>(11)</sup> In our research, men were significantly more affected than women (59.5% vs. 40.5%,  $P=0.029$ ). Some authors have found a higher prevalence of KCN in men, with values ranging from 53% to 62%,<sup>(12-16)</sup> similar to our study. Others found a dominance in women, from 53% to 66%.<sup>(12,14,17)</sup> A study by Hashemi et al. in the Middle East (Tehran, Iran) found that the overall prevalence rate of KCN was 3.3%.<sup>(14)</sup> Meanwhile, the prevalence rate was 0.8% in the 14–29-year-old group and 7.5% in those over 60.

The KCN incidence is especially high at the age of 20 to 30, but it progresses up to the age of 35. We also found this in our study, where the patients had KCN progression up to 37 years.

Our results found a greater prevalence of KCN in urban areas than in rural ones, given that urban and rural are progressively interconnected. However, according to Hashemi H, a high prevalence of KCN in Iran was found in rural areas.<sup>(4)</sup> Our results are similar to those found in the urban area of northern Iran, where the prevalence of KCN was 0.76%, but in a higher percentage.<sup>(18)</sup> According to the study by Mohaghegh et al.,<sup>(19)</sup> the likelihood of the incidence of KCN in patients with a positive family history was 20 times higher compared to patients who had a negative family history. According to Wang Y et al.,<sup>(20)</sup> the probability of KCN is 15 to 67 times higher in patients who have a positive family history.

Although the most common type of KCN is sporadic, our research found a positive family history of the illness in 10.7% of cases, similar to other research studies.<sup>(21)</sup> Of the environmental causes most frequent in the etiology of KCN was rubbing the eyes (93.4% of all respondents). Other studies also showed that eye rubbing is associated with the progress of keratoconus, even assuming whether gentle friction or vigorous knuckle-grinding rubbing impacts the progression of the disease.<sup>(22)</sup>

Other studies also found that chronic eye rubbing is linked with the development of keratoconus.<sup>(5)</sup> Some of these studies found a history of eye irritation, but others showed that eye rubbing could be caused by allergy and dry eye symptoms.<sup>(23,24)</sup> McGhee<sup>(25)</sup> found that 40% of patients with KCN had constant eye rubbing. According to Rabinowitz's study,<sup>(21)</sup> eye rubbing was found in 83% of 218 KCN patients, similar to ours. Like our study results, eye rubbing was more often related to other risk factors in Saudi Arabia studies.<sup>(26,27)</sup> Asymmetric KCN was found in some studies to be associated with the most vigorous eye rubbing.<sup>(28)</sup> Some research data show that KC develops after 14 months in case of repeated strong eye rubbing.<sup>(29)</sup> Contrary to our research results, Owens and Gamble<sup>(30)</sup> and Millodot et al.<sup>(31)</sup> found no significant association between KCN and eye friction.

There are several treatment methods available. The selection of the appropriate treatment depends on the patient's cornea parameters, the KCN progression, and the decrease in VA. KCN is the most frequent cause of ectasia, and many clinical studies have proven that corneal collagen cross-linking

(CXL) is important for halting the progression of KCN.<sup>(22,33)</sup> Based on the Dresden protocol, successful cornea crosslinking requires a minimal 400  $\mu\text{m}$  corneal thickness.<sup>(34-36)</sup> CXL was described for the first time by Wollensak et al.<sup>(34)</sup> in 2003, a corneal transplant was applied until the advent of CXL. KCN surgical treatment does not eliminate the need for specialized contact lenses because although they are more practical after surgery, they do not improve optimal vision.<sup>(36)</sup> In our study, we used the treatment CXL according to Dresden protocol, epithelial-off and epithelial-on, in patients with KCN in the early stage to prevent further progression since this is a non-invasive surgical treatment.<sup>(32,34,37)</sup> Although this method does not reverse the thinning that has already occurred, those in an early stage of KCN are potential patients, as it can prevent further progression since the risk of progression is higher at younger ages.<sup>(38,39)</sup> According to experimental and clinical findings, CXL effectiveness and the number of patients that needed to undergo the procedure have increased significantly in the last 10 years.<sup>(40)</sup> In our study, based on the clinical course of the disease as well as other risk factors, all respondents with KCN were selected in the surgically treated group (61.1%) and untreated group (38.9%). The CXL epi-on technique is more advantageous than the CXL epi-off technique, as it preserves the CT and VA and eases the postoperative pain and infection risk. However, its disadvantage is that it might fail and require further treatment.<sup>(41)</sup>

Belin ABCD represents an advanced practical staging system due to recent challenges regarding diagnosing and treating KCN.<sup>(41)</sup> In our study, KCN Stage 1 on the Amsler-Krumeich (AK) classification was predominant ( $P<0.001$ ).

Our results showed that out of 262 eyes examined, 0.8% were suspected of KCN. The cornea's tomographic assessment revealed that these changes also manifested in the other eye. Knowing that KCN is bilateral but progresses asymmetrically, patients have frequent dioptric changes depending on the stages of the disease, in which case patients experience decreased VA changes that cannot be corrected. For the diagnosis of subclinical KCN, only the topography of the front surface is not enough, and it requires the measurement of the anterior and posterior cornea.

Based on other scientific research, the frequency of suspected KCN eyes was very low since the patients were diagnosed in the early stages of KCN, like in our study.<sup>(42-44)</sup> All patients included in the study had KCN in one or both eyes. The right eye was without keratoconic manifestation in 9(6.9%) patients, without significant difference according to gender ( $P=0.739$ ), while the left eye was without keratoconic manifestation in 11(8.4%) patients without significant difference according to gender ( $P=0.999$ ).

Regarding the association between the average age of the patients and the KCN stage, it was found that 22.4% of the youngest respondents were in the advanced stage ( $P=0.235$ ). Therefore, this was a challenge for immediate treatment and efficient progression stopping. In our study, we did not obtain a statistically significant difference between the average age of patients and KCN and its stages.

Our keratometry readings found that the values of K1, K2, and the maximal corneal curvature values (Kmax) were

the lowest in the non-keratoconic and suspect eyes compared to all KCN stages ( $P < 0.001$ ).

Regarding the CT, the highest values were in the non-KCN group ( $504.0 \pm 27.6 \mu\text{m}$ ), gradually decreasing from KCN Stage 1 to Stage 4 ( $466.2 \pm 36.0 \mu\text{m}$  vs.  $378.6 \pm 95.0 \mu\text{m}$ ,  $P = 0.0000$ ).

Moreover, progression of KCN can occur with no change of Kmax, as was the case in the study by Rubinfeld and Mahmoud, who found such progression in 29 eyes.<sup>(45,46)</sup> Kmax is very often used as an indicator of ectatic progression. An increased Kmax was found in several studies but did not show an appropriate cut-off of progression.<sup>(47)</sup> According to a study by Choi et al.,<sup>(48)</sup> K1, K2, and Km rates are significantly different in non-progressing and progressing keratoconic eyes, contributing to detecting progression. We must emphasize that early ectatic alterations are apparent on the anterior surface, usually after having affected the posterior corneal surface.<sup>(49)</sup> Given that progressive corneal steepening defines KCN, endothelial damage is inevitable due to thin corneas. Therefore, suspect keratoconic eyes can be identified at their early stage<sup>(50,51)</sup> by measuring the thickness of the cornea. Our results confirm this, too: The thickness of the cornea was significantly lower in Stage 4. In the current study, uncorrected VA was significantly decreased in Stage 4 compared to Stage 1 ( $P < 0.001$ ). VA is not a reliable variable that correlates well with KCN progression, particularly if the patient wears contact lenses or spectacles.<sup>(51,52)</sup>

**In conclusion**, screening programs that detect KCN at its earliest grade are the key to enabling early management, halting progression, and preserving the quality of visual acuity.

## Ethical Considerations

The study was conducted in accordance with ethical principles of the Declaration of Helsinki (2000; revised October 2013, Fortaleza, Brazil) and was approved by the Ethics Committee at the University of Prishtina (Ref. Nr.12072).

## Competing Interests

The author declares that there is no conflict of interest.

## Acknowledgments

The author would like to thank colleagues and hospital staff for their constant support and guidance throughout the study.

## References

- Espandar L, Meyer J. Keratoconus: overview and update on treatment. *Middle East Afr J Ophthalmol*. 2010 Jan;17(1):15-20. doi: 10.4103/0974-9233.61212. PMID: 20543932; PMCID: PMC2880369.
- Najmi H, Mobarki Y, Mania K, Altowairqi B, Basehi M, Mahfouz MS, Elmahdy M. The correlation between keratoconus and eye rubbing: a review. *Int J Ophthalmol*. 2019 Nov 18;12(11):1775-1781. doi: 10.18240/ijo.2019.11.17. PMID: 31741868; PMCID: PMC6848869.
- McMonnies CW. Eye rubbing type and prevalence including contact lens 'removal-relief' rubbing. *Clin Exp Optom*. 2016 Jul;99(4):366-72. doi: 10.1111/cxo.12343. Epub 2016 Jun 16. PMID: 27306478.
- Gordon-Shaag A, Millodot M, Essa M, Garth J, Ghara M, Shneor E. Is consanguinity a risk factor for keratoconus? *Optom Vis Sci*. 2013 May;90(5):448-54. doi: 10.1097/OPX.0b013e31828da95c. PMID: 23584486.
- Gordon-Shaag A, Millodot M, Shneor E. The epidemiology and etiology of keratoconus. *Int J Keratoco Ectatic Corneal Dis*. 2012;1(1):7-15.
- Orucoglu F. Incidence and tomographic evaluation of unilateral keratoconus/Unilateral keratokonuslarda insidans ve tomografik degerlendirme. *Turkish Journal of Ophthalmology*. 2013;43(2):83-87.
- Gordon-Shaag A, Millodot M, Kaiserman I, Sela T, Barnett Itzhaki G, Zerbib Y, Matityahu E, Shkedi S, Miroshnichenko S, Shneor E. Risk factors for keratoconus in Israel: a case-control study. *Ophthalmic Physiol Opt*. 2015 Nov;35(6):673-81. doi: 10.1111/opo.12237. Epub 2015 Aug 18. PMID: 26286678.
- Ambrósio R Jr, Belin MW. Imaging of the cornea: topography vs tomography. *J Refract Surg*. 2010 Nov;26(11):847-9. doi: 10.3928/1081597X-20101006-01. PMID: 21053870.
- Winkler von Mohrenfels C, Salgado JP, Khoramnia R. Keratektasie nach refraktiver Chirurgie [Keratoconus after refractive surgery]. *Klin Monbl Augenheilkd*. 2011 Aug;228(8):704-11. German. doi: 10.1055/s-0029-1245754. Epub 2010 Nov 24. PMID: 21108164.
- Santodomingo-Rubido J, Carracedo G, Suzaki A, Villa-Collar C, Vincent SJ, Wolffsohn JS. Keratoconus: An updated review. *Cont Lens Anterior Eye*. 2022 Jun;45(3):101559. doi: 10.1016/j.clae.2021.101559. Epub 2022 Jan 4. PMID: 34991971.
- Rabinowitz YS. Keratoconus. *Surv Ophthalmol*. 1998 Jan-Feb;42(4):297-319. doi: 10.1016/s0039-6257(97)00119-7. PMID: 9493273.
- Godefrooij DA, de Wit GA, Uiterwaal CS, Imhof SM, Wisse RP. Age-specific Incidence and Prevalence of Keratoconus: A Nationwide Registration Study. *Am J Ophthalmol*. 2017 Mar;175:169-172. doi: 10.1016/j.ajo.2016.12.015. Epub 2016 Dec 28. PMID: 28039037.
- Ziaei H, Jafarinasab MR, Javadi MA, Karimian F, Poorsalman H, Mahdavi M, Shoja MR, Katibeh M. Epidemiology of keratoconus in an Iranian population. *Cornea*. 2012 Sep;31(9):1044-7. doi: 10.1097/ICO.0b013e31823f8d3c. PMID: 22710491.
- Hashemi H, Heydarian S, Yekta A, Ostadimoghaddam H, Aghamirsalim M, Derakhshan A, Khabazkhoob M. High prevalence and familial aggregation of keratoconus in an Iranian rural population: a population-based study. *Ophthalmic Physiol Opt*. 2018 Jul;38(4):447-455. doi: 10.1111/opo.12448. Epub 2018 Mar 24. PMID: 29572900.
- AMSLER M. [The "forme fruste" of keratoconus]. *Wien Klin Wochenschr*. 1961 Dec 8;73:842-3. German. PMID: 13861052.
- Ertan A, Muftuoglu O. Keratoconus clinical findings according to different age and gender groups. *Cornea*. 2008 Dec;27(10):1109-13. doi: 10.1097/ICO.0b013e31817f815a.

- PMID: 19034122.
17. Lapeyre G, Fournie P, Vernet R, Roseng S, Malecaze F, Bouzignon E, Touboul D. Keratoconus Prevalence in Families: A French Study. *Cornea*. 2020 Dec;39(12):1473-1479. doi: 10.1097/ICO.0000000000002546. PMID: 32969859.
  18. Laqua H. Hereditäre Erkrankungen beim Keratokonus [Hereditary diseases in keratoconus]. *Klin Monbl Augenheilkd*. 1971 Nov;159(5):609-18. German. PMID: 4257613.
  19. Hashemi H, Khabazkhoob M, Fotouhi A. Topographic Keratoconus is not Rare in an Iranian population: the Tehran Eye Study. *Ophthalmic Epidemiol*. 2013 Dec;20(6):385-91. doi: 10.3109/09286586.2013.848458. Epub 2013 Oct 29. PMID: 24168025.
  20. Mohaghegh S, Kangari H, Masoumi SJ, Bamdad S, Rahmani S, Abdi S, Fazil N, Shahbazi S. Prevalence and risk factors of keratoconus (including oxidative stress biomarkers) in a cohort study of Shiraz university of medical science employees in Iran. *BMC Ophthalmol*. 2023 Apr 28;23(1):188. doi: 10.1186/s12886-023-02934-0. PMID: 37106365; PMCID: PMC10142163.
  21. Rabinowitz YS. The genetics of keratoconus. *Ophthalmol Clin North Am*. 2003 Dec;16(4):607-20, vii. doi: 10.1016/s0896-1549(03)00099-3. PMID: 14741001.
  22. Balasubramanian SA, Pye DC, Willcox MD. Effects of eye rubbing on the levels of protease, protease activity and cytokines in tears: relevance in keratoconus. *Clin Exp Optom*. 2013 Mar;96(2):214-8. doi: 10.1111/cxo.12038. Epub 2013 Feb 18. PMID: 23496656.
  23. Shetty R, Sureka S, Kusumgar P, Sethu S, Sainani K. Allergen-specific exposure associated with high immunoglobulin E and eye rubbing predisposes to progression of keratoconus. *Indian J Ophthalmol*. 2017 May;65(5):399-402. doi: 10.4103/ijo.IJO\_217\_17. Erratum in: *Indian J Ophthalmol*. 2017 Jul;65(7):642-643. doi: 10.4103/0301-4738.211110. PMID: 28573997; PMCID: PMC5565884.
  24. Shneor E, Millodot M, Blumberg S, Ortenberg I, Behrman S, Gordon-Shaag A. Characteristics of 244 patients with keratoconus seen in an optometric contact lens practice. *Clin Exp Optom*. 2013 Mar;96(2):219-24. doi: 10.1111/cxo.12005. Epub 2012 Dec 20. PMID: 23278637.
  25. McGhee CN, Kim BZ, Wilson PJ. Contemporary Treatment Paradigms in Keratoconus. *Cornea*. 2015 Oct;34 Suppl 10:S16-23. doi: 10.1097/ICO.0000000000000504. PMID: 26114829.
  26. Naderan M, Shoar S, Rezagholizadeh F, Zolfaghari M, Naderan M. Characteristics and associations of keratoconus patients. *Cont Lens Anterior Eye*. 2015 Jun;38(3):199-205. doi: 10.1016/j.clae.2015.01.008. Epub 2015 Feb 21. PMID: 25707930.
  27. AlShammari Z, AlShammari R, AlOrf S, AlShammari R, AlShammari W, AlShammari W. Prevalence, clinical features and associated factors of keratoconus patients attending Ophthalmology Department, King Khalid Hospital, Hail City, Saudi Arabia. *EC Ophthalmology*. 2016;3(5):388-400.
  28. Jafri B, Lichter H, Stulting RD. Asymmetric keratoconus attributed to eye rubbing. *Cornea*. 2004 Aug;23(6):560-4. doi: 10.1097/01.ico.0000121711.58571.8d. PMID: 15256993.
  29. Hawkes E, Nanavaty MA. Eye rubbing and keratoconus: a literature review. *Int J Keratoco Ectatic Corneal Dis*. 2014;3(3):118-121.
  30. Owens H, Gamble G. A profile of keratoconus in New Zealand. *Cornea*. 2003 Mar;22(2):122-5. doi: 10.1097/00003226-200303000-00008. PMID: 12605045.
  31. Millodot M, Shneor E, Albou S, Atlani E, Gordon-Shaag A. Prevalence and associated factors of keratoconus in Jerusalem: a cross-sectional study. *Ophthalmic Epidemiol*. 2011 Apr;18(2):91-7. doi: 10.3109/09286586.2011.560747. PMID: 21401417.
  32. Baiocchi S, Mazzotta C, Cerretani D, Caporossi T, Caporossi A. Corneal crosslinking: riboflavin concentration in corneal stroma exposed with and without epithelium. *J Cataract Refract Surg*. 2009 May;35(5):893-9. doi: 10.1016/j.jcrs.2009.01.009. PMID: 19393890.
  33. Mazzotta C, Balestrazzi A, Traversi C, Baiocchi S, Caporossi T, Tommasi C, Caporossi A. Treatment of progressive keratoconus by riboflavin-UVA-induced cross-linking of corneal collagen: ultrastructural analysis by Heidelberg Retinal Tomograph II in vivo confocal microscopy in humans. *Cornea*. 2007 May;26(4):390-7. doi: 10.1097/ICO.0b013e318030df5a. PMID: 17457184.
  34. Wollensak G, Spoerl E, Seiler T. Riboflavin/ultraviolet-a-induced collagen crosslinking for the treatment of keratoconus. *Am J Ophthalmol*. 2003 May;135(5):620-7. doi: 10.1016/s0002-9394(02)02220-1. PMID: 12719068.
  35. Mastropasqua L. Collagen cross-linking: when and how? A review of the state of the art of the technique and new perspectives. *Eye Vis (Lond)*. 2015 Nov 29;2:19. doi: 10.1186/s40662-015-0030-6. PMID: 26665102; PMCID: PMC4675057.
  36. Şengör T, Aydın Kurna S. Update on Contact Lens Treatment of Keratoconus. *Turk J Ophthalmol*. 2020 Aug 26;50(4):234-244. doi: 10.4274/tjo.galenos.2020.70481. PMID: 32854468; PMCID: PMC7469902.
  37. Spoerl E, Mrochen M, Sliney D, Trokel S, Seiler T. Safety of UVA-riboflavin cross-linking of the cornea. *Cornea*. 2007 May;26(4):385-9. doi: 10.1097/ICO.0b013e3180334f78. PMID: 17457183.
  38. Larkin DFP, Chowdhury K, Burr JM, Raynor M, Edwards M, Tuft SJ, Bunce C, Caverly E, Doré C; KERALINK Trial Study Group. Effect of Corneal Cross-linking versus Standard Care on Keratoconus Progression in Young Patients: The KERALINK Randomized Controlled Trial. *Ophthalmology*. 2021 Nov;128(11):1516-1526. doi: 10.1016/j.ophtha.2021.04.019. Epub 2021 Apr 21. PMID: 33892046.
  39. Gustafsson I, Vicente A, Bergström A, Stenevi U, Ivarsen A, Hjortdal JØ. Current clinical practice in corneal crosslinking for treatment of progressive keratoconus in four Nordic countries. *Acta Ophthalmol*. 2023 Feb;101(1):109-116. doi: 10.1111/aos.15213. Epub 2022 Jul 10. PMID: 35811357; PMCID: PMC10084360.
  40. Galvis V, Tello A, Ortiz AI, Escaf LC. Patient selection for corneal collagen cross-linking: an updated review. *Clin Ophthalmol*. 2017 Apr 7;11:657-668. doi: 10.2147/OPHT. S101386. PMID: 28435217; PMCID: PMC5391157.
  41. Cifariello F, Minicucci M, Di Renzo F, Di Taranto D, Coclite G, Zaccaria S, De Turre S, Costagliola C. Epi-Off versus Epi-On Corneal Collagen Cross-Linking in Keratoconus Patients: A Comparative Study through 2-Year Follow-Up. *J Ophthalmol*. 2018 Jul 29;2018:4947983. doi: 10.1155/2018/4947983. PMID: 30151277; PMCID: PMC6087595.
  42. Belin MW, Kundu G, Shetty N, Gupta K, Mullick R,

- Thakur P. ABCD: A new classification for keratoconus. *Indian J Ophthalmol.* 2020 Dec;68(12):2831-2834. doi: 10.4103/ijo.IJO\_2078\_20. PMID: 33229658; PMCID: PMC7856970.
43. Hashemi H, Beiranvand A, Yekta A, Maleki A, Yazdani N, Khabazkhoob M. Pentacam top indices for diagnosing subclinical and definite keratoconus. *J Curr Ophthalmol.* 2016 Mar 29;28(1):21-6. doi: 10.1016/j.joco.2016.01.009. PMID: 27239598; PMCID: PMC4881219.
44. Ghassemlou N, Djalilian AR. Keratoconus; a True Corneal Disease. *J Ophthalmic Vis Res.* 2016 Jan-Mar;11(1):1-2. doi: 10.4103/2008-322X.180701. PMID: 27195077; PMCID: PMC4860973.
45. Rubinfeld RS, Littner R, Trattler WB, Rocha K, Talamo J, Lindstrom RL. Pentacam HR criteria for curvature change in keratoconus and postoperative LASIK ectasia. *J Refract Surg.* 2013 Oct;29(10):666. doi: 10.3928/1081597X-20130919-02. PMID: 24094309.
46. Mahmoud AM, Nuñez MX, Blanco C, Koch DD, Wang L, Weikert MP, Frueh BE, Tappeiner C, Twa MD, Roberts CJ. Expanding the cone location and magnitude index to include corneal thickness and posterior surface information for the detection of keratoconus. *Am J Ophthalmol.* 2013 Dec;156(6):1102-11. doi: 10.1016/j.ajo.2013.07.018. Epub 2013 Sep 25. PMID: 24075426.
47. Guber I, McAlinden C, Majo F, Bergin C. Identifying more reliable parameters for the detection of change during the follow-up of mild to moderate keratoconus patients. *Eye Vis (Lond).* 2017 Oct 25;4:24. doi: 10.1186/s40662-017-0089-3. PMID: 29124079; PMCID: PMC5655968.
48. Choi JA, Kim MS. Progression of keratoconus by longitudinal assessment with corneal topography. *Invest Ophthalmol Vis Sci.* 2012 Feb 23;53(2):927-35. doi: 10.1167/iov.11-8118. PMID: 22247476.
49. Du XL, Chen M, Xie LX. Correlation of basic indicators with stages of keratoconus assessed by Pentacam tomography. *Int J Ophthalmol.* 2015 Dec 18;8(6):1136-40. doi: 10.3980/j.issn.2222-3959.2015.06.10. PMID: 26682161; PMCID: PMC4651877.
50. Atalay E, Özalp O, Yıldırım N. Advances in the diagnosis and treatment of keratoconus. *Ther Adv Ophthalmol.* 2021 Jun 24;13:25158414211012796. doi: 10.1177/25158414211012796. PMID: 34263132; PMCID: PMC8246497.
51. Koch DD, Ali SF, Weikert MP, Shirayama M, Jenkins R, Wang L. Contribution of posterior corneal astigmatism to total corneal astigmatism. *J Cataract Refract Surg.* 2012 Dec;38(12):2080-7. doi: 10.1016/j.jcrs.2012.08.036. Epub 2012 Oct 12. PMID: 23069271.
52. Fam HB, Lim KL. Corneal elevation indices in normal and keratoconic eyes. *J Cataract Refract Surg.* 2006 Aug;32(8):1281-7. doi: 10.1016/j.jcrs.2006.02.060. PMID: 16863962.

---

**\*Correspondence:** Dr. Sci. Mimoza Ismaili. E-mail: drmimozaismaili@gmail.com

---